Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
Alok K. Tewari, Alexander T. M. Cheung, Jett Crowdis, et al.
Cell Reports (2021) Vol. 36, Iss. 10, pp. 109665-109665
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment
Jenna M. Giafaglione, Preston D. Crowell, Amelie M.L. Delcourt, et al.
Nature Cell Biology (2023) Vol. 25, Iss. 12, pp. 1821-1832
Open Access | Times Cited: 21
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity
Ivana Grbeša, Michael A. Augello, Deli Liu, et al.
Cell Reports (2021) Vol. 36, Iss. 10, pp. 109625-109625
Open Access | Times Cited: 40
Deregulation of SPOP in Cancer
Hui Zhang, Xiaofeng Jin, Haojie Huang
Cancer Research (2022) Vol. 83, Iss. 4, pp. 489-499
Open Access | Times Cited: 27
CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer
Ning Zhang, Da Huang, Xiaohao Ruan, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100912-100912
Open Access | Times Cited: 16
A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer
Yara Rodríguez, Kenji Unno, Mihai I. Truica, et al.
Cancer Research (2022) Vol. 82, Iss. 11, pp. 2110-2123
Open Access | Times Cited: 21
Race and prostate cancer: genomic landscape
Camilo Arenas‐Gallo, Jude Owiredu, Ilon Weinstein, et al.
Nature Reviews Urology (2022) Vol. 19, Iss. 9, pp. 547-561
Closed Access | Times Cited: 19
TP53 Deficiency in the Natural History of Prostate Cancer
Heidemarie Ofner, Gero Kramer, Shahrokh F. Shariat, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 645-645
Open Access
Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study
Tingwei Zhang, Beihe Wang, Wei Yu, et al.
Cell Reports Medicine (2025), pp. 102018-102018
Open Access
Genitourinary cancer neoadjuvant therapies: current and future approaches
Sujit S. Nair, Dimple Chakravarty, Vaibhav G. Patel, et al.
Trends in cancer (2023) Vol. 9, Iss. 12, pp. 1041-1057
Open Access | Times Cited: 10
Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review
Takafumi Yanagisawa, Paweł Rajwa, Fahad Quhal, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 4, pp. 641-641
Open Access | Times Cited: 7
Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
Jie Zhou, Yiming Lai, Shengmeng Peng, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial
Leonardo Cardili, Diogo Assed Bastos, Eder Nisi Ilário, et al.
World Journal of Urology (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 2
Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
Olivier Cussenot, Géraldine Cancel‐Tassin, Srinivasa R. Rao, et al.
BJU International (2023) Vol. 132, Iss. 5, pp. 472-484
Closed Access | Times Cited: 6
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer
Junjie Fan, Hua Liang, Yanan Gu, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 41, Iss. 8, pp. 354.e1-354.e9
Closed Access | Times Cited: 5
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial
Takayuki Sumiyoshi, Xiaofei Wang, Evan W. Warner, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 1, pp. 115-126
Closed Access | Times Cited: 5
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers
Ludimila Cavalcante, Sachin Kumar Deshmukh, Jennifer R. Ribeiro, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 4
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting
Andrea K. Miyahira, Sophia C. Kamran, Tamara Jamaspishvili, et al.
The Prostate (2024) Vol. 84, Iss. 11, pp. 993-1015
Closed Access | Times Cited: 1
Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access
Sarah E. Fenton, David J. VanderWeeler, Timothy R. Rebbeck, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
Ulrich Krafft, Boris Hadaschik, Katharina Lückerath, et al.
European Urology (2023) Vol. 85, Iss. 3, pp. 227-228
Closed Access | Times Cited: 2
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition
Scott Wilkinson, Anson T. Ku, Rosina T. Lis, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey‐Holden Prostate Cancer Academy Meeting
Andrea K. Miyahira, Marina N. Sharifi, Lisa N. Chesner, et al.
The Prostate (2024) Vol. 85, Iss. 3, pp. 211-226
Closed Access
Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer
Juan Gómez Rivas, Luis Enrique Ortega Polledo, Irene De La Parra Sánchez, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 99-99
Open Access
A trio of tumor suppressor miRNA downregulates CREB5 dependent transcription to modulate neoadjuvant hormonal therapy sensitivity
Xueli Wang, Bo Han, Baokai Dou, et al.
Neoplasia (2023) Vol. 36, pp. 100875-100875
Open Access | Times Cited: 1
Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer
Hyun Ho Han, Minyong Kang, Seok‐Soo Byun, et al.
Journal of Urologic Oncology (2023) Vol. 21, Iss. 2, pp. 128-139
Open Access | Times Cited: 1
Molecular Anatomy of Prostate Cancer and Its Implications in Active Surveillance and Early Intervention Strategies
Sandy Figiel, Géraldine Cancel‐Tassin, Ian G. Mills, et al.
Anatomia (2023) Vol. 2, Iss. 4, pp. 300-319
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top